Time filter

Source Type

Wang L.,Shanghai JiaoTong University | Luo X.,Shanghai JiaoTong University | Lu Y.,Shanghai JiaoTong University | Fan Z.-H.,Shanghai JiaoTong University | Hu X.,Shenzhen Beike Biotechnology Co
Annals of Plastic Surgery | Year: 2015

Cell-assisted lipotransfer (CAL) is a cotransplantation of adipose tissue and stromal vascular fraction (SVF) including adipose-derived stem cells. But although CAL can get satisfactory outcomes in breast augmentation, the resorption of the grafted fat is still unclear. A total of 12 patients received breast augmentation using CAL. All of them completed 6 months of follow-up. In 1 mini-CAL case, 500-mL liposuction fluid was used to harvest the SVF cells. In 11 full-CAL cases, 250-mL aspirated fat was needed apart from 500-mL liposuction fluid. The percentage of adipose-derived stem cells in SVF cells was detected using flow cytometry and their multilineage potential ability was assessed with in vitro induction. The volumes of breasts and pectoral muscle were measured, and radiological image change was analyzed using magnetic resonance imaging before the operation and 3 and 6 months after the operation. Additionally, the subjective evaluation on the cosmetic outcomes was determined by surgeons and patients. Adipose-derived stem cells in SVF cells accounted for 40.27% and 3.34% in full-CAL cases and mini-CAL cases, respectively. Postoperative atrophy occurred within the first 3 months. At the 6 months postoperatively, breast volume is augmented, ranging from 60.71 to 197 mL, with a mean value of 125.35 (45.49) mL. The ultimate resorption of grafted fat at the 6 months postoperatively is 51.84% (16.74%). Newly formed cysts and nodules were detected in 2 cases. No calcification was found in all magnetic resonance images. Only 1 patient was unsatisfied with the cosmetic outcome. Our preliminary study displayed a satisfactory augmented volume with little complications using CAL for breast augmentation. But the resorption at the 6 months postoperatively [51.84% (16.74%)] showed no significant advantage over non-CAL technique (40%-60% reported), which suggested that SVF cells harvested from 250-mL aspirated fat and 500-mL liposuction fluid were insufficient to average 250-mL grafted fat for each breast in this study. More SVF cells are needed to achieve lower resorption. © 2014 Wolters Kluwer Health, Inc. All rights reserved.


Li Q.,Shandong University | Li Q.,Shandong Jiaotong Hospital | Chen C.-F.,Shandong Provincial Hospital | Wang D.-Y.,Shandong Jiaotong Hospital | And 8 more authors.
Genetics and Molecular Research | Year: 2015

We aimed to evaluate the levels of growth factors in the cerebrospinal fluid (CSF) of patients with autism after transplantation of umbilical cord blood mononuclear cells (CBMNCs). Fourteen subjects diagnosed with autism received transplantation of CBMNCs first through intravenous infusion, and three times subsequently through intrathecal injections. A 2-mL sample of CSF was taken before each intrathecal injection. CSF levels of nerve growth factor (NGF), vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) were determined by enzyme-linked immunosorbent assay. All data are reported as means ± SD and were analyzed using the SPSS 10.0 software. One-way analysis of variance with post-hoc F-and Q-tests were performed for comparisons. NGF levels in the CSF were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while VEGF and bFGF levels did not change significantly. Therefore, transplantation of CBMNCs could increase NGF levels in the CSF of patients with autism. © FUNPEC-RP.


PubMed | Shandong Jiaotong Hospital, Shenzhen Beike Biotechnology Co., Shandong University and Shandong Provincial Hospital
Type: Clinical Trial | Journal: Genetics and molecular research : GMR | Year: 2015

We aimed to evaluate the levels of growth factors in the cerebrospinal fluid (CSF) of patients with autism after transplantation of umbilical cord blood mononuclear cells (CBMNCs). Fourteen subjects diagnosed with autism received transplantation of CBMNCs first through intravenous infusion, and three times subsequently through intrathecal injections. A 2-mL sample of CSF was taken before each intrathecal injection. CSF levels of nerve growth factor (NGF), vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) were determined by enzyme-linked immunosorbent assay. All data are reported as means SD and were analyzed using the SPSS 10.0 software. One-way analysis of variance with post-hoc F-and Q-tests were performed for comparisons. NGF levels in the CSF were significantly increased after transplantation (213.54 56.38 after the third versus 28.32 12.22 ng/L after the first transplantation; P < 0.05), while VEGF and bFGF levels did not change significantly. Therefore, transplantation of CBMNCs could increase NGF levels in the CSF of patients with autism.


Li Q.,Shandong Traffic Hospital | Lu Y.-T.,Shandong Traffic Hospital | Huan Y.,Shandong Traffic Hospital | Cao Y.-L.,Shenzhen Beike Biotechnology Co. | And 5 more authors.
Journal of Clinical Rehabilitative Tissue Engineering Research | Year: 2010

BACKGROUND: Transplanted neural stem cells can contribute to repair of neural function following damage through secreting or regulating some or several neurotrophic factors. OBJECTIVE: To detect levels of nerve growth factor (NGF), vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in cerebrospinal fluid in patients treated with umbilical cord blood mononuclear cells. METHODS: A total of 28 patients with nervous system disease treated with human umbilical cord blood mononuclear cells at the Shandong Traffic Hospital were enrolled. They received treatment of human umbilical cord blood mononuclear cells via lumbar puncture subarachnoid cavity, once a week, for three times. A total of 2 mL cerebrospinal fluid was maintained before each treatment. Changes in NGF, VEGF and bFGF levels were determined in patients treated with human umbilical cord blood mononuclear cells using enzyme linked immunosorbent assay, and adverse reactions were observed following transplantation. RESULTS AND CONCLUSION: NGF levels were significantly greater at 1 week after the second treatment than pretreatment and 1 week after the first treatment using one-way analysis of variance and intergroup q-test (P < 0.05). VEGF and bFGF levels were higher at 1 week after the second treatment than pretreatment and at 1 week after the first treatment (P > 0.05). There were 12 cases of low-grade fever, 4 cases of headache, 3 cases of lumbago, 4 cases of debility and 2 cases of nausea and vomiting. All were transitory symptoms, which were self relieved within several days. Results have displayed that NGF levels in cerebrospinal fluid were significantly increased in patients treated with umbilical cord blood mononuclear cells, however, VEGF and bFGF levels were not influenced significantly.


Li Q.,Shandong Hospital of Communication | Lu Y.-t.,Shandong Hospital of Communication | Huan Y.,Shandong Hospital of Communication | Liu M.,Shandong Hospital of Communication | And 6 more authors.
Chinese Journal of Tissue Engineering Research | Year: 2012

BACKGROUND: Studies have demonstrated that umbilical cord blood mononuclear cells exhibit some effects in treatment of autism. OBJECTIVE: To detect levels of nerve growth factor (NGF), vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in cerebrospinal fluid of autism patients treated with umbilical cord blood mononuclear cells. METHODS: A total of 30 autism children received treatment by injection of human umbilical cord blood mononuclear cells via lumbar puncture subarachnoid cavity, once a week, for three times totally. RESULTS AND CONCLUSION: The levels of nerve growth factors were significantly greater at 1 week after the second treatment than pretreatment and 1 week after the first treatment (P < 0.05). The levels of vascular endothelial growth factors and basic fibroblast growth factors were slightly, but not significantly, higher at 1 week after the second treatment than pretreatment and at 1 week after the first treatment (P > 0.05). Results suggest that the levels of nerve growth factors in cerebrospinal fluid were significantly increased in autism children who received treatment of umbilical cord blood mononuclear cells, however, the levels of vascular endothelial growth factors and basic fibroblast growth factors were not influenced significantly.


Chen J.-H.,North Sichuan Medical College | Hu X.,Shen Zhen Beike Biotechnology Company
Chinese Journal of Tissue Engineering Research | Year: 2015

BACKGROUND: The research for mesenchymal stem cells in the treatment of liver cirrhosis has made great progress. However, t-test analysis is often misused in clinical practice.OBJECTIVE: To analyze the efficacy and safety of umbilical cord mesenchymal stem cell therapy for liver cirrhosis by repeated measurement method.METHODS: A total of 27 patients with decompensated liver cirrhosis underwent conventional medical treatments, including liver protection treatment and symptomatic treatment. At 1 week after hospitalization, patients were given intravenous transplantation of umbilical cord mesenchymal stem cells (passages 2-4), cell viability ≥ 90%, stem cell counting ≥2x107 cells, four times with an interval of 5-7 days. Analysis of variance based on repeated measurement data was performed to analyze the liver function changes at different time after umbilical cord mesenchymal stem cell transplantation. RESULTS AND CONCLUSION: The results of univariate repeated measurement showed that at 2 and 3 months after treatment, the serum albumin level was increased and the total bilirubin level in serum was decreased significantly (P < 0.05); at 3 months after treatment, the content of aspartate aminotransferase decreased, and the content of cholinesterase increased significantly (P < 0.05). No patient appeared to have liver and other organ tumors during the observation period. These findings indicate that umbilical cord mesenchymal stem cell transplantation is effective and safe in the treatment of liver cirrhosis, which can significantly improve patient’s liver functions

Loading Shenzhen Beike Biotechnology Co. collaborators
Loading Shenzhen Beike Biotechnology Co. collaborators